2016
Role of Adjuvant Therapy for Node-Negative Lung Cancer Invading the Chest Wall
Gao SJ, Corso CD, Blasberg JD, Detterbeck FC, Boffa DJ, Decker RH, Kim AW. Role of Adjuvant Therapy for Node-Negative Lung Cancer Invading the Chest Wall. Clinical Lung Cancer 2016, 18: 169-177.e4. PMID: 27890561, DOI: 10.1016/j.cllc.2016.08.005.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerAdjuvant chemotherapyAdjuvant chemoradiation therapyUnderwent surgeryChemoradiation therapyChest wall resectionRadiation therapyMargin statusTumor sizeLung cancerWall resectionNode-negative lung cancerNational Cancer Data BaseCox proportional hazards modelMargin-positive patientsChest wall invasionCell lung cancerLog-rank testStage IIB tumorsProportional hazards modelAdjuvant therapyAdjuvant treatmentOverall survivalMultivariable analysisIIB tumorsTiming of Surgery after Neoadjuvant Chemoradiation in Locally Advanced Non–Small Cell Lung Cancer
Gao SJ, Corso CD, Wang EH, Blasberg JD, Detterbeck FC, Boffa DJ, Decker RH, Kim AW. Timing of Surgery after Neoadjuvant Chemoradiation in Locally Advanced Non–Small Cell Lung Cancer. Journal Of Thoracic Oncology 2016, 12: 314-322. PMID: 27720827, DOI: 10.1016/j.jtho.2016.09.122.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaCarcinoma, Large CellCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellChemoradiotherapy, AdjuvantCombined Modality TherapyFemaleFollow-Up StudiesHumansLung NeoplasmsMaleMiddle AgedNeoadjuvant TherapyNeoplasm StagingPneumonectomyPrognosisRetrospective StudiesSurvival RateTime FactorsConceptsNational Cancer Data BaseNeoadjuvant chemoradiationTiming of surgeryOverall survivalAdvanced non-small cell lung cancerNon-small cell lung cancerStage IIIA-N2 NSCLCStage IIIA NSCLCKaplan-Meier methodOverall survival rateSubset of patientsCell lung cancerLog-rank testMultivariate survival analysisProportional hazards modelIIIA NSCLCN2 NSCLCNeoadjuvant therapyTrimodality therapySurgical resectionClinical stageRetrospective studyLung cancerHazards modelSurvival rateLung Cancer in the Very Young: Treatment and Survival in the National Cancer Data Base
Arnold BN, Thomas DC, Rosen JE, Salazar MC, Blasberg JD, Boffa DJ, Detterbeck FC, Kim AW. Lung Cancer in the Very Young: Treatment and Survival in the National Cancer Data Base. Journal Of Thoracic Oncology 2016, 11: 1121-1131. PMID: 27103511, DOI: 10.1016/j.jtho.2016.03.023.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerNational Cancer Data BaseYounger patientsOlder patientsLung cancerRelative survivalStage IAdvanced stage non-small cell lung cancerCell lung cancerYears of ageAggressive therapyAggressive treatmentOverall survivalPatient demographicsPrimary outcomeTreatment patternsTumor characteristicsNSCLC casesPatientsStage IIIDetailed stagingSurvival informationOlder groupDistinct subsetsCancerAdjuvant Chemotherapy for T3 Non–Small Cell Lung Cancer with Additional Tumor Nodules in the Same Lobe
Salazar MC, Rosen JE, Arnold BN, Thomas DC, Kim AW, Detterbeck FC, Blasberg JD, Boffa DJ. Adjuvant Chemotherapy for T3 Non–Small Cell Lung Cancer with Additional Tumor Nodules in the Same Lobe. Journal Of Thoracic Oncology 2016, 11: 1090-1100. PMID: 27013407, DOI: 10.1016/j.jtho.2016.03.009.Peer-Reviewed Original ResearchConceptsAdditional tumor nodulesAdjuvant chemotherapyT3 tumorsSame lobeTumor nodulesPostoperative chemotherapyOverall survivalSurgical resectionSurvival advantageNon-small cell lung cancerNational Cancer Data BaseNon-small cell lungAdditional pulmonary nodulesAdjuvant chemotherapy subgroupSurvival of patientsCell lung cancerSeparate tumor nodulesChemotherapy subgroupPrimary outcomeCell lungLung cancerChemotherapyCox modelRelative survivalPatients
2015
Gender, Age, and Comorbidity Status Predict Improved Survival with Adjuvant Chemotherapy Following Lobectomy for Non-small Cell Lung Cancers Larger than 4 cm
Sandler BJ, Wang Z, Hancock JG, Boffa DJ, Detterbeck FC, Kim AW. Gender, Age, and Comorbidity Status Predict Improved Survival with Adjuvant Chemotherapy Following Lobectomy for Non-small Cell Lung Cancers Larger than 4 cm. Annals Of Surgical Oncology 2015, 23: 638-645. PMID: 26474557, DOI: 10.1245/s10434-015-4902-8.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAge FactorsAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellChemotherapy, AdjuvantCohort StudiesCombined Modality TherapyComorbidityFemaleFollow-Up StudiesHumansLung NeoplasmsMaleMiddle AgedNeoplasm StagingPneumonectomyPrognosisSex FactorsSurvival RateYoung AdultConceptsNon-small cell lung cancerAdjuvant chemotherapyNational Cancer Data BaseNon-small cell lungCharlson-Deyo scorePretreatment prognostic factorsCell lung cancerCD scoresGroup of womenGroup of menConclusionsAdjuvant chemotherapySurvival benefitT2 tumorsPrognostic factorsDistant metastasisWomen 65Cell lungLung cancerNSCLC tumorsImproved outcomesChemotherapySurgeryPatientsWomenSurvivalBolstering the Case for Lobectomy in Stages I, II, and IIIA Small-Cell Lung Cancer Using the National Cancer Data Base
Combs SE, Hancock JG, Boffa DJ, Decker RH, Detterbeck FC, Kim AW. Bolstering the Case for Lobectomy in Stages I, II, and IIIA Small-Cell Lung Cancer Using the National Cancer Data Base. Journal Of Thoracic Oncology 2015, 10: 316-323. PMID: 25319182, DOI: 10.1097/jto.0000000000000402.Peer-Reviewed Original ResearchConceptsSmall cell lung cancerNational Cancer Data BaseSurgical resectionStage ISCLC patientsSublobar resectionOverall survivalLung cancerIIIA small cell lung cancerFive-year overall survivalAddition of surgeryClinical stage IPatient underwent surgeryPrimary surgical resectionKaplan-Meier methodLikelihood of deathCurative intentComorbidity scoreUnderwent surgeryChemoradiation therapyHazard ratioMetastatic diseaseMultimodality treatmentSelect patientsTreatment regimen
2014
Impact of Adjuvant Treatment for Microscopic Residual Disease After Non-Small Cell Lung Cancer Surgery
Hancock JG, Rosen JE, Antonicelli A, Moreno A, Kim AW, Detterbeck FC, Boffa DJ. Impact of Adjuvant Treatment for Microscopic Residual Disease After Non-Small Cell Lung Cancer Surgery. The Annals Of Thoracic Surgery 2014, 99: 406-413. PMID: 25528723, DOI: 10.1016/j.athoracsur.2014.09.033.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerPositive surgical marginsCell lung cancerSurgical marginsR1 resectionNSCLC patientsResidual diseaseLung cancerNational Cancer Data BasePathologic stage IMicroscopic residual diseaseAdministration of chemotherapyOptimal treatment approachStage pIR1 patientsAdjuvant treatmentPostoperative administrationAdjuvant approachIncomplete resectionPostoperative radiationComplete resectionImproved survivalPI patientsPositive marginsSuperior survivalTreating Locally Advanced Disease: An Analysis of Very Large, Hilar Lymph Node Positive Non-Small Cell Lung Cancer Using the National Cancer Data Base
Moreno AC, Morgensztern D, Boffa DJ, Decker RH, Yu JB, Detterbeck FC, Wang Z, Rose MG, Kim AW. Treating Locally Advanced Disease: An Analysis of Very Large, Hilar Lymph Node Positive Non-Small Cell Lung Cancer Using the National Cancer Data Base. The Annals Of Thoracic Surgery 2014, 97: 1149-1155. PMID: 24582051, DOI: 10.1016/j.athoracsur.2013.12.045.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerNational Cancer Data BaseCell lung cancerOverall survivalPostoperative radiotherapyLung cancerRadiation therapyLymph Node-positive Non-small Cell Lung CancerNode-positive non-small cell lung cancerLarge non-small cell lung cancersAdvanced non-small cell lung cancerPositive non-small cell lung cancerFive-year overall survivalHilar lymph node involvementPrimary surgical therapyPrimary surgical treatmentLymph node involvementKaplan-Meier methodSurvival of patientsCox regression modelLog-rank testAdjuvant chemoradiationAdjuvant fashionAdvanced diseaseNeoadjuvant chemoradiation